ELVN logo

ENLIVEN THERAPEUTICS INC

ELVNNASDAQ
πŸ† #1482 by market capEarnings Mar 1 Β· PostUS Equity
$46.41β€”
Last available close Β· quote unavailable
πŸ””
Track ELVN
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 4.9%
14dβ–Ό 6.3%
30dβ–² 11.8%
ytdβ–² 201.6%
1yβ–² 113.6%
🏦Market Cap
$3.42B
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
56
Fair

Trading Snapshot

Day Range
β€”
52-Week Range
$14.79 – $62.32
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
73.6M
Next Earnings
2027-03-01

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-27.7
P/S Ratio
0.0x
EPS (TTM)
$-1.46
Dividend Yield
0.00%
Dilution (1yr)
+13.7%
ELVN logo

ENLIVEN THERAPEUTICS INC

ELVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$120Mβ–² +14.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$70Mβ–Ό βˆ’3.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.7Mβ–² +13.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$98Mβ–Ό βˆ’$26M YoY
StockOtter Β· stockotter.space

About ENLIVEN THERAPEUTICS INC

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100
Analyst data unavailable.

Latest News & Updates

News unavailable.